

**In vivo and in vitro analyses of MEGF10 function demonstrate its role in myoblast fusion and hypertrophic response to overload of skeletal muscle**

**Louise Richardson, Ruth Hughes, Colin A Johnson, Stuart Egginton, Michelle Peckham**

**Supplementary Material**

**Supplementary Tables**


**Supplemental Table 1: Primary Antibodies used:**

Antibody	Source	Species	Dilution (IF)	Dilution (WB)
A4.1025	ATCC hybridoma	Mouse	1:10	N/A
c-myc (9E10)	Sigma	Mouse	N/A	1:5000
GFP (AB10145)	Millipore	Rabbit	N/A	1:1000
Pax7 supernatant.	DSHB (hybridoma)	Mouse	1:20	N/A
MyoD (MA1-41017)	Thermo Scientific	Mouse	1:100	1:500
MyoD (C-20)	Santa Cruz (sc-304)	Rabbit	1:2000	N/A
Myogenin (F5D)	DSHB	Mouse	1:50	1:1000
Myogenin (MA511486)	Invitrogen	Mouse	1:50	N/A
Laminin L9393	Sigma	Rabbit	1:30	N/A
DAPI 40043	Sigma	N/A	1:500	N/A

**Supplemental Table 2. Genotypic ratio of mice born from Megf10<sup>+/-</sup> matings.** Total number of WT, heterozygous and homozygous mice and corresponding ratio.

	<b>WT</b>	<b>Heterozygous</b>	<b>Homozygous</b>
<b>Total</b>	13	20	6
<b>Ratio</b>	2	3	1


## Supplementary figures




**Supplementary Fig. 1. Primer strategy for TaqMan assay for genotyping mice.** Schematic showing forward and reverse primer, human ubiquitin C gene promoter (hUbCpro-neo-p(A)) selection cassette flanked by loxP sites and lacZ sequence within the mutant (tm1) allele. Primers used in genotyping used sequence from lacZ (Reg-LacF) and the neomycin selection cassette (tm1a allele: Reg Neo-F), the reverse primer Reg-geneR. The readout of LAC Z<sup>+</sup> WT<sup>+</sup> = heterozygous, LAC Z<sup>+</sup> WT<sup>-</sup> = homozygous, and LAC Z<sup>-</sup> WT<sup>+</sup> = wild-type.

Sequences of the genotype primers were: LAC-Z: Forward primer: CGATCGTAATCACCCGAGTGT; Reverse primer: CCGTGGCCTGACTCATTC, Reporter 1: CCAGCGACCAGATGAT; Reporter 2: N/A

And for MEGF10-1 WT; Forward primer: CTACCGGACAGCCTACCG; Reverse primer: CTTTCATAAAATCCTGGGCAACACT; Reporter 1: TATAGACGCAAATCCC, Reporter 2: N/A



**Supplemental Fig. 2: eGFP and eGFP-MEGF10 expression tests.** **A:** anti-GFP blots for MEGF10-eGFP and the GFP adenovirus expressed in cells. **B:** Localisation of MEGF10-EGFP at different MOIs. At an MOI of 50, very little signal is observed. At an MOI of 100, MEGF10-eGFP is found in vesicles and at the plasma membrane (arrowed). At MOIs of 250 and 500, most of the MEGF10-EGFP is in the Golgi (arrowed)



**Supplemental Fig 3: Expression, purification and Lectin blots for ECD and EGF.** **A and B:** Gels and blots (anti-Myc Tag) for purified extracellular domain (ECD) (**A**) and EGF domains (**B**) of MEGF10 to show the purified protein and any contaminants. **C:** SDS Page gels of Ovalbumin (Ov), ECD and EGF domains together with lectin blots using each of the specific lectins, and what they recognise, as shown.